Financial Performance
5Y price score: 170
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 383.2%
US$ Per
Share
By default your notes are visible only to you.
190.7
52-week range
267.4
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
4.2 %
Dividend Yield TTM
2.6 %
Market cap $
$ 469,596
Price / Earnings TTM
74.9
Price / Book TTM
(79.3)
PEG TTM
0.3
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
31.2 %
145.3 %
383.2 %
Free cash flow per share growth
(24.2) %
0.1 %
134.8 %
Earnings per share growth
284.9 %
(12.9) %
(24.3) %
Founded: 2,013
Employees: 55,000
Business Summary:
Latest Earnings Call Takeaways
2026 Q2 (Jul 31, 2026)
1) Strong Financial Performance - Adjusted earnings per share (EPS) reached $3.65, exceeding guidance by $0.06. - Total net revenues were nearly $17 billion, reflecting a 10.2% growth year-over-year, surpassing expectations by $300 million. - The company raised its full-year revenue guidance by $300 million, now forecasting approximately $67.6 billion in total net revenues for 2026.
2) Immunology Portfolio Growth - Immunology revenues totaled nearly $8.8 billion, with SKYRIZI sales at $5.5 billion, up 24% operationally. - RINVOQ also showed strong performance with global sales exceeding $2.5 billion, up 23.7%. - The recent approvals for RINVOQ in vitiligo and alopecia areata are expected to drive combined peak sales of nearly $2 billion.
3) Advancements in R&D and Acquisitions - AbbVie received US approval for Decnapaz, marking its entry into hematology with an antibody-drug conjugate (ADC). - The acquisition of Apogee Therapeutics is aimed at enhancing AbbVie's immunology portfolio, adding multiple assets with significant sales potential. - Ongoing clinical trials in dermatology and gastroenterology are expected to yield important data, with a focus on combination therapies.
4) Challenges and Competitive Landscape - HUMIRA sales declined to $706 million, down 36.1%, due to biosimilar competition. - The oncology segment faced a 2.4% decline in revenues, with IMBRUVICA sales down 29.4% as expected due to competitive pressures and pricing impacts. - The company is navigating a crowded market in immunology, particularly with new entrants like Eiko, but maintains confidence in the unique positioning of SKYRIZI.
5) Guidance and Future Outlook - AbbVie anticipates adjusted EPS for Q3 between $3.84 and $3.88 and expects net revenues of approximately $17.2 billion. - The company is well-positioned financially to complete the Apogee acquisition and pursue further innovative business development. - There is a strong focus on expanding the immunology pipeline and leveraging recent approvals to capture market share.
Bottom line: AbbVie is demonstrating robust financial performance and strategic growth in its immunology portfolio, supported by significant R&D advancements and a promising acquisition. Despite challenges in oncology and biosimilar competition, the company's long-term outlook remains strong, making it an attractive proposition for shareholders.
Annual Reports, Presentations And IR Contacts
Go to the websiteAbbVie Inc. — Financial Overview, Stock Price, Market Cap
AbbVie Inc. is a company. Founded in 2013. As of August 26, 2026, the company's market capitalization is $469595863894 with a current stock price of $265.79.